

## Web-only references

### Plaque stabilisation in acute coronary syndromes: clinical considerations

Adam D Timmis

1. The Scandinavian Simvastatin Survival Study (4S) Investigators. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease. *Lancet* 1994;344:1383-9
2. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. *N Engl J Med* 1998;339:1349-57.
3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Trial Investigators. *N Engl J Med* 1996;335:1001-9.
4. Brown BG, Zhao XQ, Sacco DE, Albers JJ. Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. *Circulation* 1993;1781-91.

5. Libby P, Schoenbeck U, Mach F, Selwyn AP, Ganz P. Current concepts in cardiovascular pathology: the role of LDL cholesterol in plaque rupture and stabilization. *Am J Med* 1998;104:14S-18S.
6. Second International Study of Infarct Survival (ISIS-2) Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. *Lancet* 1988; 2(8607):349-60.
7. Thrombolysis in Myocardial Ischemia (TIMI) Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB Trial. *Circulation* 1994;89:1545-56.
8. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. *N Engl J Med* 1993;329:1615-22.
9. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. *N Engl J Med* 1993;329:673-82.

10. Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. *N Engl J Med* 1997;337:1118-23.

11. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. *Lancet* 1999;354:716-22.

12. Stone GW, Grines CL, Browne KF, Marco J, Rothbaum D, O'Keefe J, Hartzler GO, Overlie P, Donohue B, Chelliah N, et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. *J Am Coll Cardiol* 1995; 25:370-7.

13. Zijlstra F, Beukema WP, van't Hof AW, Liem A, Reiffers S, Hoorntje JC, Suryapranata H, de Boer MJ. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients with acute myocardial infarction. *J Am Coll Cardiol* 1997;29:908-12.

14. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of anti-platelet therapy 1: prevention of death, myocardial infarction, and

stroke by prolonged anti-platelet therapy in various categories of patients. *BMJ* 1994;308:81-106.

15. Budaj A, Yusuf S, Mehta SR, Fox KA, Tognoni G, Zhao F, Chrolavicius S, Hunt D, Keltai M, Franzosi MG. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. *Circulation*. 2002;106:1622-6.

16. Khot UN, Nissen SE. Is CURE a cure for acute coronary syndromes? Statistical versus clinical significance. *J Am Coll Cardiol* 2002;40:218-9.

17. The Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. *Lancet* 1998;352:87-92.

18. Cannon CP. Small molecule glycoprotein IIb-IIIa receptor inhibitors as upstream therapy in acute coronary syndromes; Insights from the TACTICS TIMI-18 Trial. *J Am Coll Cardiol* 2003 (suppl S):;43S-48S.

19. Moliterno DJ, Chan AW. Glycoprotein IIb-IIIa inhibition in early intent-to-stent treatment of acute coronary syndromes: EPISTENT, ADMIRAL, CADILLAC, and TARGET. *J Am Coll Cardiol* 2003 (suppl S):;49S-54S.

20. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina.

JAMA 1996;276:811-5.

21. Kaul S, Shah PK. Low molecular weight heparin in acute coronary syndrome: evidence for superior or equivalent efficacy compared with unfractionated

heparin? J Am Coll Cardiol 2000;35:1699-712.

22. Zed PJ, Tisdale JE, Borzak S. Low-molecular-weight heparins in the management of acute coronary syndromes. Arch Intern Med. 1999;159:1849-57.

23. White HD, Aylward PE, Frey MJ, Adgey AA, Nair R, Hillis WS, Shalev Y, Brown MA, French JK, Collins R, Maraganore J, Adelman B. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 1997;96:2155-61.

24. Eikelboom J, White H, Yusuf S. The evolving role of direct thrombin inhibitors in acute coronary syndromes. J Am Coll Cardiol 2003;41 (suppl S):70S-78S.

25. Pfeffer MA, Pfeffer JM, Steinberg C, Finn P. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril.

Circulation 1985;72:406-42.

26. Sweet CS, Emmert SE, Stabilitol, Ribeiro LG. Increased survival in rats with congestive heart failure treated with enalapril. *J Cardiovasc Pharmacol* 1987;10:636-42.
27. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. *N Engl J Med* 1992;327:669-77.
28. Timmis AD, Sayer J. ACE Inhibition and Coronary Artery Disease. London. Science Press 1997.
29. Vaughan DE, Rouleau JL, Ridker PM, Arnold JM, Menapace FJ, Pfeffer MA. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. *Circulation*. 1997;96:442-7.
30. Soejima H, Ogawa H, Yasue H, Kaikita K, Takazoe K, Nishiyama K, Misumi K, Miyamoto S, Yoshimura M, Kugiyama K, Nakamura S, Tsuji I. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. *J Am Coll Cardiol* 1999;34:983-8.

31. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. *N Engl J Med* 1996;335:775-82.

32. Kleiman NS, Lincoff AM, Flaker GC, Pieper KS, Wilcox RG, Berdan LG, Lorenz TJ, Cokkinos DV, Simoons ML, Boersma E, Topol EJ, Califf RM, Harrington RA. Early percutaneous coronary intervention, platelet inhibition with eptifibatid, and clinical outcomes in patients with acute coronary syndromes. PURSUIT Investigators. *Circulation*. 2000;101:751-7.

33. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, Harrington RA, Califf RM, Ohman EM, Kleiman NS, Keltai M, Wilcox RG, Vahanian A, Armstrong PW, Lauer MS. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. *Lancet* 2001;357:1063-8.

34. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001;285:1711-8.

35. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE

(reduction of cholesterol in ischemia and function of the endothelium) trial.  
Circulation 1999;99:3227-33.

36. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss CB, Waters D.  
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic  
potential with cholesterol reduction. Circulation 1995;92:3172-7.

37. ISIS-1. Investigators. Randomised trial of intravenous atenolol among 16 027  
cases of suspected acute myocardial infarction: ISIS-1. First International Study  
of Infarct Survival Collaborative Group. Lancet 1986;2:57-66.

38. Hjalmarson A, Herlitz J, Holmberg S, Ryden L, Swedberg K, Vedin A,  
Waagstein F, Waldenstrom A, Waldenstrom J, Wedel H, Wilhelmsen L,  
Wilhelmsson C. The Goteborg metoprolol trial. Effects on mortality and morbidity  
in acute myocardial infarction. Circulation 1983;67:126-32.

39. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction.  
Mortality. The MIAMI Trial Research Group. Am J Cardiol 1985;56:15G-22G.

40. Schwartz JS, Baran KW, Bache RJ. Effect of stenosis on exercise-induced  
dilation of large coronary arteries. Am Heart J 1990;119:520-4



41. Tousoulis D, Tentolouris C, Crake T, Toutouzas P, Davies G. Basal and flow-mediated nitric oxide production by atheromatous coronary arteries. *J Am Coll Cardiol*. 1997;29:1256-62.
42. Levine SP, Towell BL, Suarez AM, Knieriem LK, Harris MM, George JN. Platelet activation and secretion associated with emotional stress. *Circulation* 1985;71:1129-34.
43. Larsson PT, Wallen NH, Martinsson A, Egberg N, Hjemdahl P. Significance of platelet beta-adrenoceptors for platelet responses in vivo and in vitro. *Thromb Haemost* 1992;68:687-93.
44. Catalano M, Russo U, Belletti S, Colombo F, Belloni A, del Rosso G, Lombardi F, Libretti A. Beta-TG and plasma catecholamines levels after sympathetic stimuli in hypertensives and patients with peripheral vascular disease. *Thromb Haemost*. 1990;63:383-5.
45. Sayer JW, Gutteridge C, Syndercombe-Court D, Wilkinson P, Timmis AD. Circadian activity of the endogenous fibrinolytic system in stable coronary artery disease: effects of beta-adrenoceptor blockers and angiotensin converting enzyme inhibitors. *J Am Coll Cardiol* 1998;32:1962-8.